Option chain shows key data for Cyclacel Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Cyclacel Pharmaceuticals.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Stock, Option Chain

Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.

Wall-Street-ai7-1

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

CRNC

CTCX

CYCC

DOGZ

IDAI

NITO

Nasdaq Surges Over 1%; Cerence Shares Spike Higher

vaccine-4892059

Cyclacel Pharmaceuticals shares are trading higher by 77% during Friday&#39;s session. The company announced a securities purchase agreement with investor David Lazar.

Why Cyclacel Pharmaceuticals (CYCC) Stock Is Skyrocketing

Wall Street Bulls

Dow Jumps Over 100 Points; ISM Manufacturing PMI Increases In December

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock

Press Releases

Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Cardiol Therapeutics' (NASDAQ: CRDL) CardiolRx™ Addresses Urgent Medical Condition Myocarditis, a Leading Cause of Sudden Cardiac Death see more stocks inside…

General

Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule

Earnings

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Financing

Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

Management

Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar

Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership

CRDL

CYCCP

GNPX

PRSO

TCBP

TSX:CRDL

Aditxt

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Alzamend Neuro

Aptevo Therapeutics

180 Life Sciences

Azitra

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Galecto

GRI Bio

GT Biopharma

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals

Mustang Bio

Moleculin Biotech

Oragenics

Onconetix

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Plus Therapeutics

SILO Pharma

Soligenix

Synaptogenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Theriva Biologics

Roth MKM

Oppenheimer

Comments

Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals (CYCC) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga